61340-15-6

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 610-37-7 5-hydroxy-2-nitrobenzoic acid 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 61340-14-5 benzyl 5-benzyloxy-2-nitrobenzoate 
• 58662-54-7 5-benzyloxy-2-nitrobenzaldehyde 

Downstream Products

• 100865-09-6 1-(5-benzyloxy-2-nitro-phenyl)-2-bromo-ethanone 
• 847861-76-1 5-benzyloxy-N,N-dimethyl-2-nitrobenzamide 
• 116027-17-9 2-amino-5-benzyloxybenzoic acid methyl ester 
• 116027-21-5 6-(benzyloxy)-2-chloro-3,4-dihydroquinazoline 
• 116027-19-1 6-(benzyloxy)-2,4-dichloroquinazoline 
• 116027-16-8 methyl 5-(benzyloxy)-2-nitrobenzoate 
• 116027-18-0 methyl 5-(benzyloxy)-2-ureidobenzoate 
• 116027-23-7 7-(benzyloxy)-1,2,3,5-tetrahydro-2-oxoimidazo<2,1-b>quinazoline 
• 116027-22-6 ethyl <6-(benzyloxy)-2-chloro-3,4-dihydroquinazolin-3-yl>acetate 
• 65883-84-3 2-amino-5-(benzyloxy)benzamide 
• 102656-57-5 (5-benzyloxy-2-nitro-phenacyl)-formylamino-malonic acid diethyl ester 
• 103039-32-3 2-amino-4-(5-hydroxy-2-nitro-phenyl)-4-oxo-butyric acid 
• 499973-08-9 N-(5-benzyloxy-2-nitrobenzoyl)-L-proline methyl ester 
• 945989-78-6 C₁₆H₂₀N₂O 

Relevant academic research and scientific papers

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

A new class of histamine H3 receptor antagonists derived from ligand based design

Design and synthesis of highly potent and selective non-imidazole inverse agonists for the histamine H3 receptor is described. The study validates a new pharmacophore model based on the merging of two previously described models. It also demonstrates that the removal of the basic center potentially interacting with ASP3.32 and common to both models leads to loss of activity, whereas the replacement of the second basic center by an acceptor retains the potency.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of Formula (1) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.

An expedient synthesis of 7-O-functionalised pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones

An efficient synthetic route to 7-hydroxypyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione, an important potential ligand for the DNA minor groove, has been developed. Simultaneous reduction of nitro and hydrogenolysis of the O-benzyl in N-(5-benzyloxy-2-nitro

Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline

Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.